This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Caixeta, A. Articles by Mehran, R. PubMed Articles by Caixeta, A. Articles by Mehran, R. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation

Insights From a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents With Bare-Metal Stents

Adriano Caixeta, MD, PhD^_*, Martin B. Leon, MD^_*, Alexandra J. Lansky, MD^_*, Eugenia Nikolsky, MD, PhD^_*, Jiro Aoki, MD, PhD^_*, Jeffrey W. Moses, MD^_*, Joachim Schofer, MD, Marie-Claude Morice, MD, Erick Schampaert, MD, Ajay J. Kirtane, MD, SM^_*, Jeffrey J. Popma, MD^||, Helen Parise, DSc^_*, Martin Fahy, MSc^_* and Roxana Mehran, MD^_*,_*

^_* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Hamburg University Cardiovascular Center, Hamburg, Germany
Institut Cardiovasculaire Paris Sud, Massy, France
Hôpital du Sacre-Coeur de Montréal, Montréal, Quebec, Canada
^|| St. Elisabeth Medical Center, Boston, Massachusetts

Manuscript received November 4, 2008; revised manuscript received April 6, 2009, accepted April 7, 2009.

^_* Reprint requests and correspondence: Dr. Roxana Mehran, 161 Fort Washington Avenue, 5th Floor, New York, New York 10032 (Email: rmehran{at}crf.org).

Objectives: Five-year clinical follow-up has been scheduled per protocol by the 4 Cypher (Cordis/Johnson & Johnson, Warren, New Jersey) sirolimus-eluting stent (SES) versus bare-metal stent (BMS) randomized trials.

Background: A delayed arterial healing response after drug-eluting stent implantation has raised concerns about the long-term safety of drug-eluting stents.

Methods: In a pooled analysis of 4 randomized trials, 1,748 patients were assigned to receive either an SES (n = 878) or BMS (n = 870).

Results: At 5 years, there was no significant difference in the rate of death, myocardial infarction (MI), or the composite of death/MI between the 2 groups (15.1% in the SES group vs. 13.6% in the BMS group; p = 0.36). The 5-year incidence of stent thrombosis by the Academic Research Consortium definition did not differ between SES and BMS (definite/probable stent thrombosis, 2.1% vs. 2.0%; p = 0.99). The incidence of very late stent thrombosis was also similar between the SES and BMS groups (1.4% vs. 0.7%; p = 0.22). The annualized rates of definite/probable stent thrombosis after 1 year were 0.4% for SES and 0.2% for BMS. The 5-year incidence of target vessel revascularization was significantly lower in the SES group (15.2% vs. 30.1%; p < 0.0001).

Conclusions: In this patient-level pooled analysis, overall use of SES compared with BMS demonstrated persistent superior efficacy at 5 years in terms of a reduction in target vessel revascularization, without an increase in rates of death, MI, or stent thrombosis. (The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study, NCT00233805 [ClinicalTrials.gov] ; The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions, NCT00381420 [ClinicalTrials.gov] ; Study of Sirolimus-Coated BX VELOCITY Balloon-Expandable Stent in Treatment of de Novo Native Coronary Artery Lesions [SIRIUS], NCT00232765 [ClinicalTrials.gov] ; The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions, NCT00235144 [ClinicalTrials.gov] )

Key Words: drug-eluting stent • stent • restenosis • thrombosis • long term

Abbreviations and Acronyms   ARC = Academic Research Consortium   BMS = bare-metal stent(s)   DES = drug-eluting stent(s)   MI = myocardial infarction   SES = sirolimus-eluting stent(s)   TLR = target lesion revascularization   TVR = target vessel revascularization

Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A29. [Full Text] [PDF]